8-K: Catheter Precision Reports 200% Revenue Growth, Completes Flyte Acquisition

Catheter Precision announced a 200% year-over-year revenue increase to $432,000 for Q1 2026, driven by its medical device segment and the newly acquired aviation platform, Flyte, while also reducing its net loss.

Summary

• Catheter Precision reported a 200% increase in first-quarter revenue, reaching $432,000 compared to $143,000 in Q1 2025.
• This growth was fueled by both the company's medical device segment and its new aviation platform, Flyte.
• The net loss for the quarter significantly decreased to $1.7 million from $4.0 million in the prior year's first quarter.
• The acquisition of Flyte, an aviation company, has been integrated and is already contributing revenue, with plans to expand its fleet.
• The medical device segment saw a 73% revenue increase, with products now used in 15 countries and supported by new clinical publications.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive report due to significant revenue growth, substantial reduction in net loss, and successful integration of a high-growth acquisition.

Positives

• First quarter revenue grew 200% year-over-year to $432,000.
• Net loss reduced to $1.7 million, a substantial improvement from $4.0 million in Q1 2025.
• The Flyte acquisition is contributing immediate revenue, achieving a $200,000 monthly run rate within 22 days of operations.
• Medical device segment revenue increased approximately 73%.
• Adoption of VIVO and LockeT expanded across multiple new institutions.
• Products are now utilized in 15 countries worldwide.
• New clinical publications validated LockeT and VIVO technologies.
• Breakthrough research presented at the Heart Rhythm Society Congress.

Negatives

• The company still reported a net loss of $1.7 million for the quarter.
• The net loss includes approximately $560,000 in non-cash expenses (depreciation, amortization, stock-based compensation).

Risks

• Forward-looking statements are subject to substantial risks and uncertainties.
• Actual outcomes may differ materially due to uncertainties, risks, and changes in circumstances, including those detailed in the Company's Form 10-K filed with the SEC.

Future Outlook

The company is positioned for scalable, high-impact expansion with a dual-engine growth platform combining medical devices and aviation. Flyte expects to add 2 additional jets by the end of Q2 2026 and is filing applications to expand service into international markets. The company anticipates presenting new research at the Heart Rhythm Society Congress.

Management Comments

• Catheter Precision is now uniquely positioned as a dual-engine growth platform.
• This differentiated model provides multiple pathways to growth, diversified revenue streams, and the ability to capture value across both healthcare and mobility markets.
• Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.

Industry Context

StockSavvy.ai notes that Catheter Precision's strategic diversification into regional air mobility via the Flyte acquisition represents a bold move to leverage high-growth sectors. The combination of a clinically validated medical device business with a technology-enabled aviation platform aims to create a unique, multi-faceted growth engine, a strategy increasingly seen in companies seeking to diversify revenue and capture value across disparate but potentially synergistic markets.

Comparison to Industry Standards

• No direct comparisons to specific industry standards or competitors were provided in the filing for the medical device segment.
• For the aviation segment, the filing mentions targeting underserved short-haul markets with high-frequency demand, a strategy employed by other regional air mobility startups.
• The 200% revenue growth is exceptionally high, significantly outperforming typical growth rates in the mature medical device sector, but is more aligned with early-stage technology or acquisition-driven growth in emerging sectors like regional air mobility.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth and strategic diversification.
• Employees: Positive impact from company growth and expansion, potentially leading to new opportunities.
• Customers (Medical Devices): Continued access to innovative electrophysiology technologies with growing clinical validation.
• Customers (Aviation): Access to faster, safer, and more efficient regional air travel options.
• Suppliers: Potential for increased business as the company scales operations in both segments.

Next Steps

• Expand Flyte's fleet with 2 additional jets by the end of Q2 2026.
• Expand Flyte's service into international markets including Toronto and the Bahamas.
• Continue commercial penetration of medical devices across new hospitals in the U.S. and Europe.
• Present breakthrough research at the Heart Rhythm Society Congress.

Key Dates

Recommendation

The filing demonstrates exceptional revenue growth driven by both core business expansion and a highly successful strategic acquisition. The significant reduction in net loss, coupled with clear future growth catalysts in both the medical device and aviation sectors, presents a compelling investment case for substantial upside potential.

Keywords

Catheter Precision, Flyte Acquisition, Medical Devices, Revenue Growth, Aviation, Electrophysiology, Ventricular Arrhythmias, Q1 2026 Results